Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions

Future Medicinal Chemistry

Volumn 4, Issue 5, 2012, Pages 681-693

  Baneyx, Guillaume ^a   Fukushima, Yumi ^a   Parrott, Neil ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; CERIVASTATIN; CYCLOSPORIN; DILTIAZEM; FLUOROURACIL; GEMFIBROZIL; ITRACONAZOLE; KETOCONAZOLE; MIBEFRADIL; OMEPRAZOLE; SAQUINAVIR; SIMVASTATIN; TRIAZOLAM;

ADVERSE OUTCOME; COMPUTER PROGRAM; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG METABOLISM; DRUG TRANSPORT; GRAPEFRUIT JUICE; HUMAN; IN VITRO STUDY; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SIMULATION;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG DISCOVERY; DRUG INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SOFTWARE;

EID: 84859456583     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.13     Document Type: Review

References (59)

1. Hansten PD, Horn JR. Drug Interactions Analysis and Management. Wolters Kluwer Health, MO, USA (2005).
2. Reimche L, Forster AJ, van Walraven C. Incidence and contributors to potential drug-drug interactions in hospitalized patients. J. Clin. Pharmacol. 51(7), 1043 (2010).
3. Jonker DM, Visser SAG, van der Graaf PH et al. Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol. Ther. 106, 1-18 (2005). (Pubitemid 40386718)
4. Thakrar BT, Grundschober SB, Doessegger L. Detecting signals of drug-drug interactions in a spontaneous reports database. Br. J. Clin. Pharmacol. 64(4), 489-495 (2007). (Pubitemid 47404296)
5. Diasio RB. Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br. J. Clin. Pharmacol. 46(1), 1-4 (1998). (Pubitemid 28308417)
6. Shitara Y, Hirano M, Sato H et al. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)- mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol Exp. Ther. 311(1), 228-236 (2004). (Pubitemid 39287802)
7. Chin TW, Loeb M, Fong IW et al. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob. Agents Chemother. 39(8), 1671-1675 (1995).
8. Kruse JA. Metformin-associated lactic acidosis. J. Emerg. Med. 20(3), 267-272 (2001). (Pubitemid 32218683)
9. Somogyi A, Stockley C, Keal J et al. Reduction of metformin renal tubular secretion by cimetidine in man. Br. J. Clin. Pharmacol. 23, 545-551 (1987). (Pubitemid 17087957)
10. Tsuda M, Terada T, Ueba M et al. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J. Pharmacol. Exp. Ther. 329, 185-191 (2009).
11. Giacomini K, Huang S, Tweedie D. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9(3), 215-236 (2010).
12. Fromm MF, Kim RB, Glaeser H. Importance of P-glycoprotein for drug-drug interactions. In: Drug Transporters. Springer, Berlin, Germany, 285-297 (2011).
13. Eyal S, Hsiao P, Unadkat JD. Drug interactions at the blood-brain barrier: Fact or fantasy? Pharmacol. Ther. 123(1), 80-104 (2009).
14. Poirier A, Funk C, Lave T, Noe J. New strategies to address drug-drug interactions involving OATPs. Curr. Opin. Drug Discov. Dev. 10, 74-83 (2007). (Pubitemid 46438260)
15. Watanabe T, Kusuhara H, Sugiyama Y. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. J. Pharmacokinet. Pharmacodyn. 37(6), 575 (2010).
16. Guengerich F. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 8(1), E101-E111 (2006).
17. Fowler S, Zhang H. in vitro evaluation of reversible and irreversible cytochrome P450 inhibition: Current status on methodologies and their utility for predicting drug-drug interactions. AAPS J. 10(2), 410 (2008).
18. Hewitt NJ, Lechón MJ, Houston JB et al. Primary hepatocytes: Current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev. 39(1), 159-234 (2007).
19. Hewitt NJ, Lecluyse EL, Ferguson SS. Induction of hepatic cytochrome P450 enzymes: Methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 37(10-11), 1196-1224 (2007). (Pubitemid 350035534)
20. Heikkinen AT, Mönkkönen J. Protein concentration and pH affect the apparent P-glycoprotein-ATPase activation kinetics. Intl J. Pharm. 346(1-2), 169-172 (2008). (Pubitemid 350101985)
21. Heikkinen AT, Korjamo T, Lepikkö V et al. Effects of experimental setup on the apparent concentration dependency of active efflux transport in in vitro cell permeation experiments. Mol. Pharm. 7(2), 605-617 (2010).
22. Miliotis T, Ali L, Palm JE et al. Development of a highly sensitive method using LC-MRM to quantify membrane P-glycoprotein in biological matrices and relationship to transport function. Drug Metab. Dispos. 39(12), 2440 (2011).
23. Uchida Y, Ohtsuki S, Kamiie J et al. Blood-brain barrier (BBB) pharmacoproteomics: Reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J. Pharmacol. Exp. Ther. 339(2), 579-588 (2011).
24. Bjornsson TD, Callaghan JT, Einolf HJ et al. The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective. J Clin. Pharmacol. 43(5), 443-469 (2003). (Pubitemid 36506147)
25. Jones H, Parrott N, Jorga K et al. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin. Pharm. 45(5), 511-542 (2006).
26. Rowland M, Matin SB. Kinetics of drug-drug interactions. J. Pharmacokinet. Pharmacodyn. 1(6), 553-567 (1973).
27. Ito K, Iwatsubo T, Kanamitsu S et al. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu. Rev. Pharmacol. Toxicol. 38, 461-499 (1998). (Pubitemid 28231503)
28. Einolf HJ. Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 37(10), 1257-1294 (2007). (Pubitemid 350035530)
29. Rostami-Hodjegan A, Tucker G. In silico simulations to assess the in vivo consequences of in vitro metabolic drug-drug interactions. Drug Discov. Today Technol. 1(4), 441-448 (2004). (Pubitemid 40186348)
30. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol. 51(1), 45-73 (2011).
31. Jones HM, Gardner IB, Collard WT et al. Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling. Clin. Pharmacokinet. 50(5), 331-347 (2011).
32. Bjorkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: Theophylline and midazolam as model drugs Br. J. Clin. Pharmacol. 59(6), 691-704 (2005). (Pubitemid 40835503)
33. Parrott N, Davies B, Hoffmann G et al. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. Clin. Pharmacokinet. 50(9), 613-623 (2011).
34. Rowland Yeo K, Aarabi M, Jamei M, Rostami-Hodjegan A. Modeling and predicting drug pharmacokinetics in patients with renal impairment. Exp. Rev. Clin. Pharmacol. 4(2), 261-274 (2011).
35. Edginton AN, Willmann S. Physiology-based simulations of a pathological condition: Prediction of pharmacokinetics in patients with liver cirrhosis. Clin. Pharmacokinet. 47(11), 743-752 (2008).
36. Cubitt HE, Rowland Yeo K, Howgate EM et al. Sources of inter-individual variability in IVIVE of clearance: An investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica 41(8), 623-638 (2011).
37. Inoue S, Howgate EM, Rowland Yeo K et al. Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences. Xenobiotica 36(6), 499-513 (2006). (Pubitemid 43890729)
38. Rodgers T, Rowland M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm. Res. 24(5), 918-933 (2007). (Pubitemid 46675393)
39. Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug. Discov. 6(2), 140-148 (2007). (Pubitemid 46745341)
40. Sugano K. Introduction to computational oral absorption simulation. Exp. Opin. Drug Metab. Toxicol. 5(3), 259-293 (2009).
41. Zhao P, Ragueneau-Majlessi I, Zhang L et al. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: A simulation study. J. Clin. Pharmacol. 49(3), 351-359 (2009).
42. Poirier A, Cascais AC, Funk C, Lave T. Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J. Pharmacokinet. Pharmacodyn. 36(6), 585-611 (2009).
43. Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Prediction of intestinal first-pass drug metabolism. Curr. Drug Metab. 8(7), 676-684 (2007). (Pubitemid 47578116)
44. Bruyere A, Decleves X, Bouzom F et al. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK Models for predicting intestinal first pass. Mol. Pharm. 7(5), 1596-1607 (2010).
45. Wang Y-H. Confidence assessment of the simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors. Drug Metab. Dispos. 38(7), 1094-1104 (2010).
46. Rowland Yeo K, Jamei M, Yang J, Tucker GT, Rostami-Hodjegan A. Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut. The effect of diltiazem on the time-course of exposure to triazolam. Eur. J. Pharm. Sci. 39(5), 298-309 (2010).
47. Lukacova V, Parrott N, Howard M, Woltosz W, Bolger M. Prediction of omeprazole's disposition and drug-drug interactions using a physiologically- based pharmacokinetic model. Presented at: ADMET Europe 2010. Munich, Germany, 8-9 April 2010.
48. Howgate M, Rowland-Yeo K, Proctor N, Tucker GT, Rostami-Hodjegan A. Prediction of in vivo drug clearance from in vitro data: Impact of inter-individual variability. Xenobiotica 36(6), 473-497 (2006). (Pubitemid 43890728)
49. Willmann, S, Hohn K, Edginton A et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J. Pharmacokinet. Pharmacodyn. 34(3), 401-431 (2007). (Pubitemid 46873033)
50. Vossen M, Sevestre M, Niederalt C et al. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Theor. Biol. Med. Model. 4(13) (2007).
51. Perdaems N, Blasco H, Vinson C et al. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Clin. Pharmacokinet. 49(4), 239-258 (2010).
52. Chien JY, Lucksiri A, Charles SE et al. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab. Dispos. 34(7), 208-1219 (2006).
53. Fenneteau F, Poulin P, Nekka F. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J. Pharm. Sci. 99(1), 486-514 (2010).
54. US FDA. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. US FDA, Silver Spring, MD, USA (2004).
55. Jones, H. M., M. Dickins, Youdim K et al. Application of PBPK modelling in drug discovery and development at Pfizer. Xenobiotica 42(1), 94-106 (2012).
56. Lalonde RL, Kowalski KG, Hutmacher MM et al. Model-based drug development. Clin. Pharmacol. Ther. 82(1), 21-32 (2007). (Pubitemid 46950619)
57. Zhao P, Zhang L, Grillo JA et al. Applications of PBPK modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 89(2), 259-267 (2011).
58. Kamiie J, Ohtsuki S, Iwase R et al. Quantitative atlas of membrane transporter proteins: Development.and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in silico peptide selection criteria. Pharm. Res. 25(6), 1469-1483 (2008).
59. Poirier A, Funk C, Scherrmann JM et al. Mechanistic modeling of hepatic transport from cells to whole body: Application to napsagatran and fexofenadine. Mol. Pharm. 6(6), 1716-1733 (2009).